PDF(Pubmed)
Abstract：
(1) Background: Metformin, an anti-diabetic drug, seems to protect against aggressive acquisition in colorectal cancers (CRCs). However, its mechanisms are still really unknown, raising questions about the possibility of its positive impact on non-diabetic patients with CRC. (2) Methods: An in vitro study based on human colon cancer cell lines and an ex vivo study with different colon cancer stages with proteomic and transcriptomic analyses were initiated. (3) Results: Metformin seems to protect from colon cancer invasive acquisition, irrespective of glucose concentration. (4) Conclusions: Metformin could be used as an adjuvant treatment to surgery for both diabetic and non-diabetic patients in order to prevent the acquisition of aggressiveness and, ultimately, recurrences.
摘要：
（1）背景：二甲双胍，一种抗糖尿病药物，似乎可以防止结肠直肠癌（CRC）的侵袭性获取。然而,它的机制仍然未知，提出了关于其对非糖尿病CRC患者的积极影响的可能性的疑问。(2)方法:开始基于人结肠癌细胞系的体外研究和具有蛋白质组和转录组分析的不同结肠癌分期的离体研究。（3）结果：二甲双胍似乎可以保护结肠癌的侵袭性获得，与葡萄糖浓度无关。(4)结论:二甲双胍可作为糖尿病和非糖尿病患者手术的辅助治疗,最终,复发。
